Technical Analysis for IMMU - Immunomedics, Inc.

Grade Last Price % Change Price Change
grade D 15.61 -2.80% -0.45
IMMU closed down 2.8 percent on Friday, May 17, 2019, on 87 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical IMMU trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Crossed Above 20 DMA Bullish -2.80%
Calm After Storm Range Contraction 4.55%
20 DMA Resistance Bearish 1.30%
1,2,3 Retracement Bearish Bearish Swing Setup 1.30%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.30%
MACD Bullish Signal Line Cross Bullish 1.30%
Shooting Star Candlestick Bearish 4.77%

Older signals for IMMU ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Biotechnology Biopharmaceutical Cancer Immunology Treatment Of Cancer Monoclonal Antibodies Pharmacology Serious Diseases Pancreatic Cancer Non Hodgkin Lymphoma Humanized Antibody Lupus NHL Leukemias Treatment Of Pancreatic Cancer Cd20 Milatuzumab Treatment Of Lupus Treatment Of Non Hodgkin Lymphoma
Is IMMU a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 27.33
52 Week Low 11.55
Average Volume 2,562,828
200-Day Moving Average 18.8331
50-Day Moving Average 16.9806
20-Day Moving Average 15.446
10-Day Moving Average 14.978
Average True Range 0.8984
ADX 31.47
+DI 17.5659
-DI 20.0375
Chandelier Exit (Long, 3 ATRs ) 14.8648
Chandelier Exit (Short, 3 ATRs ) 16.2452
Upper Bollinger Band 17.1023
Lower Bollinger Band 13.7897
Percent B (%b) 0.55
BandWidth 21.446329
MACD Line -0.4667
MACD Signal Line -0.6105
MACD Histogram 0.1439
Fundamentals Value
Market Cap 1.74 Billion
Num Shares 111 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -10.62
Price-to-Sales 396.34
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.51
Resistance 3 (R3) 16.60 16.40 16.36
Resistance 2 (R2) 16.40 16.17 16.35 16.31
Resistance 1 (R1) 16.00 16.03 15.90 15.91 16.26
Pivot Point 15.80 15.80 15.75 15.75 15.80
Support 1 (S1) 15.40 15.57 15.30 15.31 14.96
Support 2 (S2) 15.20 15.43 15.15 14.91
Support 3 (S3) 14.80 15.20 14.86
Support 4 (S4) 14.71